Nikita Shah sold $1.6M of AMRX
Executive Vice President at Amneal Pharmaceuticals, Inc.. 131,856 shares at an average of $11.92, traded Nov 12, 2025, filed Nov 14, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 47% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-052413, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2025 | MOption exercise Class A Common Stock | +36,331 | $2.75 | $100k | 182,734 | Nov 14, 2025 |
| Nov 12, 2025 | MOption exercise Class A Common Stock | +95,525 | $2.75 | $263k | 278,259 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Class A Common Stock | -131,856 | $11.92 | $1.6M | 146,403 | Nov 14, 2025 |
| Nov 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -36,331 | $0.00 | $0 | 0 | Nov 14, 2025 |
| Nov 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -95,525 | $0.00 | $0 | 0 | Nov 14, 2025 |
Related signals
Other insiders at Amneal Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Amneal Pharmaceuticals, Inc. | Ted C Nark director | $586k 50,000 shares | -15% | |
| 49Moderate | Amneal Pharmaceuticals, Inc. | John Kiely director | $295k 32,000 shares | -12% | |
| 65Notable | Amneal Pharmaceuticals, Inc. | Nikita Shah Executive Vice President | $1.2M 120,832 shares | -45% | |
| 60Notable | Amneal Pharmaceuticals, Inc. | Andrew S Boyer Executive Vice President | $2.6M 279,244 shares | -65% | |
| 82Strong | Amneal Pharmaceuticals, Inc. | Tasos Konidaris Executive Vice President & CFO | $4.7M 499,730 shares | -80% | |
| 55Moderate | Amneal Pharmaceuticals, Inc. | Nikita Shah Executive Vice President | $666k 71,694 shares | -21% | |
| 49Moderate | Amneal Pharmaceuticals, Inc. | Andrew S Boyer Executive Vice President | $303k 33,436 shares | -12% | |
| 62Notable | Amneal Pharmaceuticals, Inc. | Jason B. Daly EVP, Chief Legal Officer | $199k 22,000 shares | -67% | |
| 52Moderate | Amneal Pharmaceuticals, Inc. | Nikita Shah Executive Vice President | $452k 50,000 shares | -13% | |
| 17Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $761k 94,906 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.